ANNX · Insider Trading
Annexon, Inc. Common Stock
Every open-market purchase and sale reported by ANNX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-25 | Douglas Love | PRESIDENT AND CEO | Buy | +26,065 | +$99.83K |
| 2026-08-12 | Mark S. Blumenkranz | Director | A | +175,000 deriv. | — |
| 2026-06-15 | Muneer A Satter | Director | A | +65,000 deriv. | — |
| 2026-06-15 | William A Jones Jr | Director | A | +65,000 deriv. | — |
| 2026-06-15 | Bettina M. Cockroft | Director | A | +65,000 deriv. | — |
| 2026-06-15 | William H. Carson | Director | A | +65,000 deriv. | — |
| 2026-06-15 | Jung Choi | Director | A | +65,000 deriv. | — |
| 2026-06-15 | William D. Waddill | Director | A | +65,000 deriv. | — |
| 2026-06-15 | Ted Yednock | EVP & CHIEF INNOVATION OFFICER | M | +30,646 | +$56.70K |
| 2026-05-29 | Muneer A Satter | Director | Buy | +613,497 | +$3.32M |
| 2026-05-13 | William H. Carson | Director | Buy | +8,000 | +$46.24K |
| 2026-04-14 | William H. Carson | Director | Buy | +8,000 | +$49.60K |
| 2026-03-12 | William H. Carson | Director | Buy | +8,000 | +$45.36K |
| 2026-03-04 | Dean Richard Artis | EVP & CHIEF SCIENTIFIC OFFICER | Sell | −5,894 | −$32.00K |
| 2026-03-04 | Michael Overdorf | EVP & CHIEF BUSINESS OFFICER | Sell | −4,339 | −$23.52K |
| 2026-03-04 | Jennifer Lew | EVP & CHIEF FINANCIAL OFFICER | Sell | −5,565 | −$30.16K |
| 2026-03-04 | Jamie Dananberg | CHIEF MEDICAL OFFICER | Sell | −5,820 | −$31.60K |
| 2026-03-04 | Ted Yednock | EVP & CHIEF INNOVATION OFFICER | Sell | −5,566 | −$30.17K |
| 2026-02-23 | Jamie Dananberg | CHIEF MEDICAL OFFICER | A | +56,250 | — |
| 2026-02-23 | Douglas Love | PRESIDENT AND CEO | A | +1,250,000 deriv. | — |
| 2026-02-23 | Ted Yednock | EVP & CHIEF INNOVATION OFFICER | A | +62,500 | — |
| 2026-02-23 | Michael Overdorf | EVP & CHIEF BUSINESS OFFICER | A | +62,500 | — |
| 2026-02-23 | Dean Richard Artis | EVP & CHIEF SCIENTIFIC OFFICER | A | +62,500 | — |
| 2026-02-23 | Jennifer Lew | EVP & CHIEF FINANCIAL OFFICER | A | +62,500 | — |
| 2026-02-20 | Michael Overdorf | EVP & CHIEF BUSINESS OFFICER | Sell | −6,225 | −$31.75K |
| 2026-02-20 | Jamie Dananberg | CHIEF MEDICAL OFFICER | Sell | −5,290 | −$26.98K |
| 2026-02-20 | Jennifer Lew | EVP & CHIEF FINANCIAL OFFICER | Sell | −7,851 | −$40.12K |
| 2026-02-20 | Ted Yednock | EVP & CHIEF INNOVATION OFFICER | Sell | −7,857 | −$40.15K |
| 2026-02-20 | Dean Richard Artis | EVP & CHIEF SCIENTIFIC OFFICER | Sell | −5,290 | −$26.98K |
| 2026-01-02 | William H. Carson | Director | Buy | +4,115 | +$20.66K |
| 2025-12-03 | Jung Choi | Director | Buy | +33,000 | +$138.27K |
| 2025-12-03 | William H. Carson | Director | Buy | +4,115 | +$18.39K |
| 2025-11-21 | Muneer A Satter | Director | Buy | +822,613 | +$3.60M |
| 2025-11-19 | Muneer A Satter | Director | Buy | +1,500,000 | +$5.05M |
| 2025-10-31 | William H. Carson | Director | Buy | +4,115 | +$13.04K |
| 2025-10-02 | William H. Carson | Director | Buy | +4,115 | +$12.55K |
| 2025-09-04 | William H. Carson | Director | Buy | +4,115 | +$8.60K |
| 2025-08-01 | William H. Carson | Director | Buy | +4,115 | +$10.00K |
| 2025-07-16 | Ted Yednock | EVP & CHIEF INNOVATION OFFICER | Sell | −1,116 | −$2.88K |
| 2025-07-16 | Jennifer Lew | EVP & CHIEF FINANCIAL OFFICER | Sell | −1,117 | −$2.88K |
| 2025-07-16 | Michael Overdorf | EVP & CHIEF BUSINESS OFFICER | Sell | −853 | −$2.23K |
| 2025-07-01 | William H. Carson | Director | Buy | +4,115 | +$10.12K |
| 2025-06-09 | William H. Carson | Director | A | +55,000 deriv. | — |
| 2025-06-09 | William A Jones Jr | Director | A | +55,000 deriv. | — |
| 2025-06-09 | Bettina M. Cockroft | Director | A | +55,000 deriv. | — |
| 2025-06-09 | Muneer A Satter | Director | A | +55,000 deriv. | — |
| 2025-06-09 | William D. Waddill | Director | A | +55,000 deriv. | — |
| 2025-06-09 | Jung Choi | Director | A | +55,000 deriv. | — |
| 2025-06-09 | Thomas G Wiggans | Director | A | +55,000 deriv. | — |
| 2025-03-03 | Douglas Love | PRESIDENT AND CEO | A | +1,300,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Muneer A Satter | Director | 10,342,134 | $40.85M |
| Douglas Love | PRESIDENT AND CEO | 390,476 | $1.54M |
| Ted Yednock | EVP & CHIEF INNOVATION OFFICER | 184,807 | $729.99K |
| Michael Overdorf | EVP & CHIEF BUSINESS OFFICER | 182,625 | $721.37K |
| Dean Richard Artis | EVP & CHIEF SCIENTIFIC OFFICER | 180,093 | $711.37K |
| Jennifer Lew | EVP & CHIEF FINANCIAL OFFICER | 170,700 | $674.26K |
| Jamie Dananberg | CHIEF MEDICAL OFFICER | 123,582 | $488.15K |
| William H. Carson | Director | 78,405 | $309.70K |
| Jung Choi | Director | 33,000 | $130.35K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ANNX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.